Literature DB >> 24021025

Preclinical toxicology and biodistribution studies of recombinant adeno-associated virus 1 human acid α-glucosidase.

Thomas J Conlon1, Kirsten Erger, Stacy Porvasnik, Travis Cossette, Cheryl Roberts, Lynn Combee, Saleem Islam, Jeffry Kelley, Denise Cloutier, Nathalie Clément, Corinne R Abernathy, Barry J Byrne.   

Abstract

A biodistribution and toxicology study was performed to test the acute toxicities of intradiaphragmatic injection of a recombinant adeno-associated virus (rAAV) 2/1-human acid alpha-Glucosidase (hGAA) driven by a cytomegalovirus (CMV) promoter (rAAV1-CMV-hGAA) in New Zealand white rabbits and in the rodent Pompe disease model by injecting at the right quadriceps. Studies performed using fluoroscopy and AAV2-GFP demonstrated spread upon intradiaphragmatic injection, and the ability of AAV to infect and express acid α-glucosidase (GAA) throughout the diaphragm. For the preclinical study, 10 rabbits (5 male, 5 female) were divided into two groups, vehicle control (Lactated Ringer's) and test article (1.5×10(12) vector genomes [vg] rAAV1-CMV-hGAA), and euthanized on day 21. After direct visualization, the left hemidiaphragm was injected at three locations. There was up to a 2,500-fold increase in circulating anti-AAV1 antibodies directed to the vector capsids. In addition, up to an 18-fold increase in antibodies against the GAA protein was generated. Injection sites maintained up to 1.0×10(5) vg/μg genomic DNA (gDNA), while uninjected sites had up to 1.0×10(4) vg/μg gDNA. Vector DNA was present in blood at 24 hr postinjection at up to 1.0×10(6) vg/μg gDNA, followed by a decrease to 1.0×10(3) vg/μg gDNA at euthanization on day 21. Nominal amounts of vector DNA were present in peripheral organs, including the brain, spinal cord, gonads, and skeletal muscle. Upon histopathological examination, fibroplasias of the serosal surface were noted at diaphragm injections sites of both groups. In addition, an increase in mononuclear cell infiltration in the diaphragm and esophagus in vector-dosed animals was found. Elevated creatine phosphokinase levels, an indicator of muscle repair, was observed in all animals postprocedure but persisted in vector-injected rabbits until euthanization. A follow-up study suggested that this was directed against the human transgene expression in a foreign species. Overall, this study demonstrates diffusion of vector throughout the diaphragm after localized injections.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24021025      PMCID: PMC4003472          DOI: 10.1089/humc.2013.147

Source DB:  PubMed          Journal:  Hum Gene Ther Clin Dev        ISSN: 2324-8637            Impact factor:   5.032


  25 in total

1.  Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors.

Authors:  H Chao; P E Monahan; Y Liu; R J Samulski; C E Walsh
Journal:  Mol Ther       Date:  2001-09       Impact factor: 11.454

Review 2.  Production of recombinant adeno-associated virus vectors.

Authors:  S Zolotukhin
Journal:  Hum Gene Ther       Date:  2005-05       Impact factor: 5.695

Review 3.  Gene therapy clinical trials worldwide to 2012 - an update.

Authors:  Samantha L Ginn; Ian E Alexander; Michael L Edelstein; Mohammad R Abedi; Jo Wixon
Journal:  J Gene Med       Date:  2013-02       Impact factor: 4.565

4.  Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors.

Authors:  Cathryn Mah; Christina A Pacak; Kerry O Cresawn; Lara R Deruisseau; Sean Germain; Melissa A Lewis; Denise A Cloutier; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2007-01-23       Impact factor: 11.454

5.  Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.

Authors:  Thomas J Fraites; Mary R Schleissing; R Andrew Shanely; Glenn A Walter; Denise A Cloutier; Irene Zolotukhin; Daniel F Pauly; Nina Raben; Paul H Plotz; Scott K Powers; Paul D Kessler; Barry J Byrne
Journal:  Mol Ther       Date:  2002-05       Impact factor: 11.454

Review 6.  Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).

Authors:  Nina Raben; Paul Plotz; Barry J Byrne
Journal:  Curr Mol Med       Date:  2002-03       Impact factor: 2.222

7.  Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects.

Authors:  Sihong Song; Marda Scott-Jorgensen; Jianming Wang; Amy Poirier; James Crawford; Martha Campbell-Thompson; Terence R Flotte
Journal:  Mol Ther       Date:  2002-09       Impact factor: 11.454

8.  Enzyme replacement therapy in the mouse model of Pompe disease.

Authors:  N Raben; M Danon; A L Gilbert; S Dwivedi; B Collins; B L Thurberg; R J Mattaliano; K Nagaraju; P H Plotz
Journal:  Mol Genet Metab       Date:  2003 Sep-Oct       Impact factor: 4.797

9.  Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II.

Authors:  N Raben; K Nagaraju; E Lee; P Kessler; B Byrne; L Lee; M LaMarca; C King; J Ward; B Sauer; P Plotz
Journal:  J Biol Chem       Date:  1998-07-24       Impact factor: 5.157

10.  Pompe disease diagnosis and management guideline.

Authors:  Priya S Kishnani; Robert D Steiner; Deeksha Bali; Kenneth Berger; Barry J Byrne; Laura E Case; Laura Case; John F Crowley; Steven Downs; R Rodney Howell; Richard M Kravitz; Joanne Mackey; Deborah Marsden; Anna Maria Martins; David S Millington; Marc Nicolino; Gwen O'Grady; Marc C Patterson; David M Rapoport; Alfred Slonim; Carolyn T Spencer; Cynthia J Tifft; Michael S Watson
Journal:  Genet Med       Date:  2006-05       Impact factor: 8.822

View more
  11 in total

1.  Charting a clear path: the ASGCT Standardized Pathways Conference.

Authors:  Hans-Peter Kiem; Christopher Baum; Frederic D Bushman; Barry J Byrne; Barrie J Carter; Joy Cavagnaro; Harry L Malech; Jerry R Mendell; Luigi M Naldini; Brian P Sorrentino; David A Williams; Terence R Flotte
Journal:  Mol Ther       Date:  2014-07       Impact factor: 11.454

2.  Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease.

Authors:  Adrian G Todd; Jessica A McElroy; Robert W Grange; David D Fuller; Glenn A Walter; Barry J Byrne; Darin J Falk
Journal:  Ann Neurol       Date:  2015-06-30       Impact factor: 10.422

3.  Efficient CRISPR/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA.

Authors:  Andrés Felipe Leal; Carlos Javier Alméciga-Díaz
Journal:  Gene Ther       Date:  2022-05-18       Impact factor: 5.250

4.  Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease.

Authors:  Manuela Corti; Cristina Liberati; Barbara K Smith; Lee Ann Lawson; Ibrahim S Tuna; Thomas J Conlon; Kirsten E Coleman; Saleem Islam; Roland W Herzog; David D Fuller; Shelley W Collins; Barry J Byrne
Journal:  Hum Gene Ther Clin Dev       Date:  2017-12       Impact factor: 5.032

Review 5.  Pompe disease: literature review and case series.

Authors:  Majed Dasouki; Omar Jawdat; Osama Almadhoun; Mamatha Pasnoor; April L McVey; Ahmad Abuzinadah; Laura Herbelin; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

6.  Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease.

Authors:  Phillip A Doerfler; Adrian G Todd; Nathalie Clément; Darin J Falk; Sushrusha Nayak; Roland W Herzog; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2016-01       Impact factor: 5.695

Review 7.  Gene therapy in monogenic congenital myopathies.

Authors:  Xuan Guan; Melissa A Goddard; David L Mack; Martin K Childers
Journal:  Methods       Date:  2015-10-14       Impact factor: 3.608

Review 8.  Manufacturing of recombinant adeno-associated viral vectors for clinical trials.

Authors:  Nathalie Clément; Joshua C Grieger
Journal:  Mol Ther Methods Clin Dev       Date:  2016-03-16       Impact factor: 6.698

Review 9.  Targeted approaches to induce immune tolerance for Pompe disease therapy.

Authors:  Phillip A Doerfler; Sushrusha Nayak; Manuela Corti; Laurence Morel; Roland W Herzog; Barry J Byrne
Journal:  Mol Ther Methods Clin Dev       Date:  2016-01-27       Impact factor: 6.698

Review 10.  Scalable downstream strategies for purification of recombinant adeno- associated virus vectors in light of the properties.

Authors:  Weihong Qu; Mingxi Wang; Yaqing Wu; Ruian Xu
Journal:  Curr Pharm Biotechnol       Date:  2015       Impact factor: 2.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.